Korean J Med.
2010 Apr;78(4):527-530.
Successful treatment of refractory livedoid vasculitis with rituximab and cyclophosphamide
- Affiliations
-
- 1Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. ymkang@knu.ac.kr
Abstract
- Livedoid vasculitis (LV) is a chronic recurrent cutaneous disease that is characterized by a netlike vascular pattern of purpuric lesions that progress to ulcers and atrophic white scars. The etiology of LV is unknown. Various therapies have been used for LV with inconsistent results, including antiplatelet agents, fibrinolytics, anticoagulants, prostaglandin E1, and immunosuppressive agents, such as systemic corticosteroids, azathioprine, methotrexate, cyclosporine, and mycophenolate mofetil. We present a patient with idiopathic LV refractory to immunosuppressive therapy who had a good response to treatment with rituximab and cyclophosphamide.
Keyword
MeSH Terms
-
Adrenal Cortex Hormones
Alprostadil
Antibodies, Monoclonal, Murine-Derived
Anticoagulants
Azathioprine
Cicatrix
Cyclophosphamide
Cyclosporine
Humans
Immunosuppressive Agents
Methotrexate
Mycophenolic Acid
Platelet Aggregation Inhibitors
Ulcer
Vasculitis
Rituximab
Adrenal Cortex Hormones
Alprostadil
Antibodies, Monoclonal, Murine-Derived
Anticoagulants
Azathioprine
Cyclophosphamide
Cyclosporine
Immunosuppressive Agents
Methotrexate
Mycophenolic Acid
Platelet Aggregation Inhibitors
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Three Cases of Livedoid Vasculitis Improved by Low-dose Danazol
- A Case of Relapsing Granulomatosis with Polyangiitis Treated Successfully with Rituximab
- Ischemic Neuropathy Associated with Livedoid Vasculitis
- Rituximab Treatment for the Patient with Refractory Lupus Nephritis
- Successful Treatment of Refractory Cutaneous Polyarteritis Nodosa with Adalimumab
